Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/16/2019 07/17/2019 07/18/2019 07/19/2019 07/22/2019 Date
66.94(c) 66.92(c) 67.21(c) 65.04(c) 64.91 Last
5 573 167 4 858 469 4 002 492 8 876 391 6 302 747 Volume
-1.66% -0.03% +0.43% -3.23% -0.20% Change
More quotes
Financials (USD)
Sales 2019 22 022 M
EBIT 2019 11 470 M
Net income 2019 7 013 M
Debt 2019 5 794 M
Yield 2019 3,88%
Sales 2020 22 381 M
EBIT 2020 11 427 M
Net income 2020 6 986 M
Finance 2020 3 308 M
Yield 2020 4,13%
P/E ratio 2019 12,3x
P/E ratio 2020 11,7x
EV / Sales2019 4,01x
EV / Sales2020 3,54x
Capitalization 82 537 M
More Financials
Company
Gilead Sciences specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (98.5% of net sales) and other (1.5%; primarily... 
Sector
Biotechnology & Medical Research
Calendar
07/22 | 12:00pmPresentation
More about the company
Surperformance© ratings of Gilead Sciences
Trading Rating : Investor Rating :
More Ratings
Latest news on GILEAD SCIENCES
12:01pGILEAD SCIENCES : Presents New Data on Biktarvy® for the Treatment of HIV in Wom..
BU
11:37aGILEAD SCIENCES : Says Study of GS-6207 Showed HIV Capsid Inhibition Can Lead Vi..
DJ
11:01aGILEAD SCIENCES : Presents Proof-of-Concept Data for GS-6207, a First-in-Class C..
BU
09:56aGILEAD SCIENCES : Licenses Respiratory and Herpes Antiviral Research Programs fr..
AQ
08:54aGILEAD SCIENCES : Licenses Durect's Saber Technology for Injectable HIV Product
DJ
07/19GILEAD SCIENCES : Murad Ali Shah says his government working hard to contain spr..
AQ
07/19SINDH GOVT ALLOCATES RS 600M TO CONT : CM Sindh
AQ
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/19GILEAD SCIENCES : Licenses Respiratory and Herpes Antiviral Research Programs Fr..
BU
07/19GILEAD SCIENCES : Sindh govt allocates Rs600m to contain HIV, says Murad
AQ
More news
Analyst Recommendations on GILEAD SCIENCES
More recommendations
Sector news : Bio Therapeutic Drugs
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/16As steep patent cliff looms, Shionogi moves to develop its own U.S. sales sta..
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15The Galapagos drugs pipeline that has drawn in Gilead
RE
More sector news : Bio Therapeutic Drugs
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 80,65  $
Last Close Price 64,91  $
Spread / Highest target 46,4%
Spread / Average Target 24,3%
Spread / Lowest Target -9,10%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES3.98%82 702
VERTEX PHARMACEUTICALS5.08%44 598
REGENERON PHARMACEUTICALS-20.18%32 544
GENMAB14.24%11 908
SAREPTA THERAPEUTICS INC36.77%11 068
ARRAY BIOPHARMA INC226.25%10 372